-
公开(公告)号:EP1773384B1
公开(公告)日:2015-08-12
申请号:EP05856778.5
申请日:2005-06-01
申请人: Icahn School of Medicine at Mount Sinai , ST. JUDE CHILDREN'S RESEARCH HOSPITAL , The United States of America as represented by the Secretary of Agriculture
发明人: GARCIA-SASTRE, Adolfo , PALESE, Peter , LAGER, Kelly, M. , WEBSTER, Robert , RICHT, Juergen, A. , WEBBY, Richard, J.
IPC分类号: A61K39/00 , A61K39/12 , A61K39/145 , C12N15/64 , C12N5/00 , A61K39/116
CPC分类号: A61K39/145 , A61K39/12 , A61K2039/5254 , A61K2039/5256 , A61K2039/544 , A61K2039/552 , A61K2039/58 , C12N7/00 , C12N2760/16034 , C12N2760/16061 , C12N2760/16121 , C12N2760/16134 , C12N2760/16151 , C12N2760/16171
-
公开(公告)号:EP1773384A2
公开(公告)日:2007-04-18
申请号:EP05856778.5
申请日:2005-06-01
申请人: THE MOUNT SINAI SCHOOL OF MEDICINE, OF THE CITY UNIVERSITY OF NEW YORK , ST. JUDE CHILDREN'S RESEARCH HOSPITAL , The United States of America as represented by the secretary of Agriculture
发明人: GARCIA-SASTRE, Adolfo , PALESE, Peter , LAGER, Kelly, M. , WEBSTER, Robert , RICHT, Juergen, A. , WEBBY, Richard, J.
IPC分类号: A61K39/00 , A61K39/12 , A61K39/145 , C12N15/64 , C12N5/00 , A61K39/116
CPC分类号: A61K39/145 , A61K39/12 , A61K2039/5254 , A61K2039/5256 , A61K2039/544 , A61K2039/552 , A61K2039/58 , C12N7/00 , C12N2760/16034 , C12N2760/16061 , C12N2760/16121 , C12N2760/16134 , C12N2760/16151 , C12N2760/16171
摘要: The present invention relates, in general, to attenuated swine influenza viruses having an impaired ability to antagonize the cellular interferon (IFN) response, and the use of such attenuated viruses in vaccine and pharmaceutical formulations. In particular, the invention relates to attenuated swine influenza viruses having modifications to a swine NS1 gene that diminish or eliminate the ability of the NS1 gene product to antagonize the cellular IFN response. These viruses replicate in vivo, but demonstrate decreased replication, virulence and increased attenuation, and therefore are well suited for use in live virus vaccines, and pharmaceutical formulations.
摘要翻译: 本发明一般涉及具有拮抗细胞干扰素(IFN)应答能力受损的减毒猪流感病毒,以及在疫苗和药物制剂中使用这种减毒病毒。 具体地,本发明涉及具有修饰的猪NS1基因的减毒猪流感病毒,其减少或消除NS1基因产物拮抗细胞IFN应答的能力。 这些病毒在体内复制,但表现出降低的复制,毒力和增加的衰减,因此非常适合用于活病毒疫苗和药物制剂。
-
3.
公开(公告)号:EP4404961A1
公开(公告)日:2024-07-31
申请号:EP22869532.6
申请日:2022-09-20
申请人: Laboratorio Avi-Mex, S.A. De C.V. , Consejo Nacional De Humanidades, Ciencias Y Tecnologías , Icahn School of Medicine at Mount Sinai
-
公开(公告)号:EP4151232A1
公开(公告)日:2023-03-22
申请号:EP21804807.2
申请日:2021-02-22
发明人: LOZANO-DUBERNARD, Bernardo , SOTO-PRIANTE, Ernesto , SARFATI-MIZRAHI, David , CASTRO-PERALTA, Felipa , PAZ-DE LA ROSA, Georgina , PALESE, Peter , GARCIA-SASTRE, Adolfo , KRAMMER, Florian , SUN, Weina
IPC分类号: A61K39/215 , C12N15/86 , A61P31/14
摘要: An active or inactivated recombinant vaccine against COVID-19 is described that comprises a Newcastle disease viral vector and a pharmaceutically acceptable carrier, adjuvant and/or excipient, characterized in that the viral vector is a virus capable of generating a cellular immune response that has a SARS-CoV-2 exogenous nucleotide sequence inserted.
-
公开(公告)号:EP4225366A1
公开(公告)日:2023-08-16
申请号:EP21878555.8
申请日:2021-10-07
IPC分类号: A61K39/39 , A61K47/60 , A61K31/4745 , A61K31/80
-
6.
公开(公告)号:EP4146674A2
公开(公告)日:2023-03-15
申请号:EP21800838.1
申请日:2021-05-06
IPC分类号: C07K14/165 , C07K14/005
-
7.
公开(公告)号:EP4110803A1
公开(公告)日:2023-01-04
申请号:EP21760173.1
申请日:2021-02-26
发明人: SKOBE, Mihaela , EDWARDS, Andrew, Kenneth , FERNANDEZ-RODRIGUEZ, Ruben , GARCIA-SASTRE, Adolfo , MENA, Ignacio , CUADRADO CASTAÑO, Sara
IPC分类号: C07K14/71 , A61P35/00 , A61K35/768
-
公开(公告)号:EP2536425B1
公开(公告)日:2019-06-19
申请号:EP11745345.6
申请日:2011-02-18
-
公开(公告)号:EP3471767A1
公开(公告)日:2019-04-24
申请号:EP17813990.3
申请日:2017-06-14
IPC分类号: A61K39/12 , A61K39/145 , C07K14/005 , C12N7/00
-
公开(公告)号:EP2987856B1
公开(公告)日:2018-07-25
申请号:EP15162322.0
申请日:2010-02-05
IPC分类号: C12N7/00 , A61K35/76 , C07K14/125 , C07K14/11
CPC分类号: C12N7/00 , A61K35/13 , A61K39/0011 , A61K39/17 , C07K14/005 , C12N2760/16122 , C12N2760/18121 , C12N2760/18122 , C12N2760/18132 , C12N2760/18143 , C12N2760/18171
摘要: The invention provides chimeric Newcastle disease viruses (NDV) engineered to express a heterologous interferon antagonist, a modified F protein, and a cytokine. Further provided are pharmaceutical compositions comprising such chimeric viruses, methods for producing said pharmaceutical compositions and their use in a method for treating cancer in a subject. Provided are also cells and non-human embryonated eggs comprising the chimeric NDV viruses of the invention.
-
-
-
-
-
-
-
-
-